Traditional methods of target discovery have relied on in vitro/ in vivo studies and sometimes molecular dynamics analysis. However, these methods are ad hoc and do not use the systems biology approach based on mechanistic understanding of the underlying biology. Target identification is a key step in drug development. Based on systematic literature review in disease, targets are identified from a cell or microenvironment. Differential sensitivity of individual drugs and molecular targets in computational models are validated with in vivo and in vitro experimental data from the literature repository. Finally, validated computational models could be set as an initiative to eradicate repetitive wet lab experiments. Target identification and validation would be concurrently used to test the combination of different drugs. PancreaSolve’s access and use of CytoSolve®’s in silico mechanistic models provide a breakthrough methodology to discover and validate targets cheaper and faster. A stellar example is CytoSolve’s work with Alnylam’s Alnylam Pharmaceuticals, a leading provider of siRNA therapeutics has validated CytoSolve’s in silico predictions for Hereditary Angioedema (HAE), using their in vivo mouse models, thus accelerating Alnylam’s development process.